ONTX Onconova Therapeutics, Inc.

+0  (2%)
Previous Close 2.08
Open 2.20
Price To book 3.27
Market Cap 14.42M
Shares 6,772,000
Volume 324,912
Short Ratio 7.97
Av. Daily Volume 157,234

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial planned. Protocol for proposed trial to be submitted to FDA in 2Q or 3Q 2017.
Oral Rigosertib and azacitidine 09-08 trial
Myelodysplastic Syndromes (MDS) and Acute myeloid leukemia (AML) cancer
Original Phase 3 trial did not meet endpoint in Feb 2014. However, following "subgroup analyses" and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018.
IV Rigosertib - INSPIRE
2nd-line HR-MDS (high risk myelodysplastic syndromes)

Latest News

  1. Onconova Therapeutics Announces Closing of Public Offering of Common Stock
  2. Onconova Therapeutics, Inc. to Present at PIONEERS 2017 Presented by Joseph Gunnar & Co., LLC
  3. Onconova Therapeutics stock drops 12% after pricing stock offering
  4. Onconova Therapeutics Announces Pricing of Public Offering of Common Stock
  5. Onconova Therapeutics Announces Proposed Public Offering of Common Stock
  6. Company News for April 05, 2017
  7. Onconova Therapeutics and Pluristem Therapeutics Surge as Candidate Drugs Move Closer to Final Approval
  8. Onconova Reports Positive Data for 2 Cancer Drugs
  9. Onconova Therapeutics stock surges 18% on positive pre-clinical data for cancer drugs
  10. Onconova Therapeutics Announces Positive Preclinical Data for Third-Generation Oral CDK4/6 + ARK5 Inhibitor and dual FLT3 and Src inhibitor at 2017 American Association of Cancer Research (AACR) Annual Meeting
  11. Onconova Therapeutics, Inc. :ONTX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 31, 2017
  12. Edited Transcript of ONTX earnings conference call or presentation 27-Mar-17 1:00pm GMT
  13. Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2016 Financial Results
  14. Onconova Therapeutics, Inc. to Present at Two Upcoming Healthcare Conferences
  15. Onconova Therapeutics, Inc. to Provide Corporate Update and Full Year 2016 Financial Results
  16. Onconova Therapeutics, Inc. to Present at Two Healthcare Conferences in March
  17. Onconova Therapeutics, Inc. to Present at Two Investor Conferences in February
  18. These 5 Stocks Under $10 Could Get Hot Soon
  19. SeeThruEquity Initiates Coverage on Onconova Therapeutics, Inc. (NASDAQ: ONTX) with a Price Target of $5.00